Patents by Inventor Steven D.E. Sullivan
Steven D.E. Sullivan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230218597Abstract: The present disclosure provides inhibitors of activin receptor-like kinase 5 (ALK5). Also disclosed are methods to modulate the activity of ALK5 and methods of treatment of disorders mediated by ALK5.Type: ApplicationFiled: January 4, 2023Publication date: July 13, 2023Inventors: Christina Owens, Svitlana Kulyk, Steven D.E. Sullivan, Paul Allegretti, Mandy Loo, Jennifer Kozak, Chen Zhao, Erik Fenster, Adam D. Hughes
-
Publication number: 20230063643Abstract: The invention provides compounds of formula (I): which contain a 4-membered heterocyclic amide, where the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat respiratory diseases, and processes and intermediates useful for preparing such compounds.Type: ApplicationFiled: August 10, 2022Publication date: March 2, 2023Inventors: PAUL R. FATHEREE, GARY E.L. BRANDT, CAMERON SMITH, STEVEN D.E. SULLIVAN, LORI JEAN VAN ORDEN, MELANIE A. KLEINSCHEK, GLENN D. CRATER
-
Publication number: 20220306624Abstract: The invention provides compounds of formula (I): wherein X is and the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat respiratory diseases, and processes and intermediates useful for preparing such compounds.Type: ApplicationFiled: March 7, 2022Publication date: September 29, 2022Applicant: THERAVANCE BIOPHARMA R&D IP, LLCInventors: Paul R. Fatheree, John R. Jacobsen, Anne-Marie Beausoleil, Gary E.L. Brandt, Melissa Fleury, Lan Jiang, Cameron Smith, Steven D.E. Sullivan, Lori Jean Van Orden, Pierre-Jean Colson, Gene Timothy Fass, Miroslav Rapta, Noah Benjamin, Marta Dabros, Venkat R. Thalladi
-
Publication number: 20210269436Abstract: The invention provides compounds of formula (I): which contain a 4-membered heterocyclic amide, where the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat respiratory diseases, and processes and intermediates useful for preparing such compounds.Type: ApplicationFiled: February 12, 2021Publication date: September 2, 2021Applicant: THERAVANCE BIOPHARMA R&D IP, LLCInventors: PAUL R. FATHEREE, GARY E.L. BRANDT, CAMERON SMITH, STEVEN D.E. SULLIVAN, LORI JEAN VAN ORDEN
-
Publication number: 20210154178Abstract: The present disclosure provides inhibitors of activin receptor-like kinase 5 (ALK5). Also disclosed are methods to modulate the activity of ALK5 and methods of treatment of disorders mediated by ALK5.Type: ApplicationFiled: December 4, 2020Publication date: May 27, 2021Applicant: THERAVANCE BIOPHARMA R&D IP, LLCInventors: Svitlana Kulyk, Christina Owens, Steven D.E. Sullivan, Jennifer Kozak, Adam D. Hughes
-
Publication number: 20210154179Abstract: The present disclosure provides inhibitors of activin receptor-like kinase 5 (ALK5). Also disclosed are methods to modulate the activity of ALK5 and methods of treatment of disorders mediated by ALK5.Type: ApplicationFiled: November 20, 2020Publication date: May 27, 2021Applicant: THERAVANCE BIOPHARMA R&D IP, LLCInventors: Christina Owens, Svitlana Kulyk, Steven D.E. Sullivan, Paul Allegretti, Mandy Loo, Jennifer Kozak, Erik Fenster, Adam D. Hughes
-
Publication number: 20210130351Abstract: The invention provides compounds of formula (I): wherein X is and the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat respiratory diseases, and processes and intermediates useful for preparing such compounds.Type: ApplicationFiled: January 5, 2021Publication date: May 6, 2021Applicant: THERAVANCE BIOPHARMA R&D IP, LLCInventors: Paul R. Fatheree, John R. Jacobsen, Gary E.L. Brandt, Melissa Fleury, Lan Jiang, Cameron Smith, Steven D.E. Sullivan, Lori Jean Van Orden, Anne-Marie Beausoleil
-
Publication number: 20200216447Abstract: The invention provides compounds of formula (I): which contain a 4-membered heterocyclic amide, where the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat respiratory diseases, and processes and intermediates useful for preparing such compounds.Type: ApplicationFiled: December 3, 2019Publication date: July 9, 2020Applicant: THERAVANCE BIOPHARMA R&D IP, LLCInventors: PAUL R. FATHEREE, GARY E.L. BRANDT, CAMERON SMITH, STEVEN D.E. SULLIVAN, LORI JEAN VAN ORDEN
-
Publication number: 20200188370Abstract: The present disclosure provides inhibitors of activin receptor-like kinase 5 (ALK5). Also disclosed are methods to modulate the activity of ALK5 and methods of treatment of disorders mediated by ALK5.Type: ApplicationFiled: December 10, 2019Publication date: June 18, 2020Applicant: THERAVANCE BIOPHARMA R&D IP, LLCInventors: Svitlana Kulyk, Christina Owens, Steven D.E. Sullivan, Jennifer Kozak, Adam D. Hughes
-
Publication number: 20200181141Abstract: The invention provides compounds of formula (I): where the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat respiratory diseases, and processes and intermediates useful for preparing such compounds.Type: ApplicationFiled: November 11, 2019Publication date: June 11, 2020Applicant: THERAVANCE BIOPHARMA R&D IP, LLCInventors: PAUL R. FATHEREE, GARY E.L. BRANDT, CAMERON SMITH, STEVEN D.E. SULLIVAN, LORI JEAN VAN ORDEN
-
Publication number: 20190337945Abstract: The invention provides compounds of formula (I): which contain a 4-membered heterocyclic amide, where the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat respiratory diseases, and processes and intermediates useful for preparing such compounds.Type: ApplicationFiled: July 15, 2019Publication date: November 7, 2019Applicant: THERAVANCE BIOPHARMA R&D IP, LLCInventors: Paul R. FATHEREE, Gary E.L. Brandt, Cameron Smith, Steven D.E. Sullivan, Lori Jean Van Orden, Melanie A. Kleinschek, Glenn D. Crater
-
Publication number: 20190127371Abstract: The invention provides compounds of formula (I): where the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat respiratory diseases, and processes and intermediates useful for preparing such compounds.Type: ApplicationFiled: December 19, 2018Publication date: May 2, 2019Applicant: THERAVANCE BIOPHARMA R&D IP, LLCInventors: PAUL R. FATHEREE, GARY E.L. BRANDT, CAMERON SMITH, STEVEN D.E. SULLIVAN, LORI JEAN VAN ORDEN, MELANIE A. KLEINSCHEK, GLENN D. CRATER
-
Publication number: 20190119275Abstract: The invention provides compounds of formula (I): which contain a 4-membered heterocyclic amide, where the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat respiratory diseases, and processes and intermediates useful for preparing such compounds.Type: ApplicationFiled: December 17, 2018Publication date: April 25, 2019Applicant: THERAVANCE BIOPHARMA R&D IP, LLCInventors: PAUL R. FATHEREE, GARY E.L. BRANDT, CAMERON SMITH, STEVEN D.E. SULLIVAN, LORI JEAN VAN ORDEN, MELANIE A. KLEINSCHEK, GLENN D. CRATER
-
Publication number: 20190106420Abstract: The invention provides compounds of formula (I): wherein X is and the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat respiratory diseases, and processes and intermediates useful for preparing such compounds.Type: ApplicationFiled: December 10, 2018Publication date: April 11, 2019Applicant: THERAVANCE BIOPHARMA R&D IP, LLCInventors: Paul R. Fatheree, John R. Jacobsen, Gary E.L. Brandt, Melissa Fleury, Lan Jiang, Cameron Smith, Steven D.E. Sullivan, Lori Jean Van Orden, Anne-Marie Beausoleil
-
Publication number: 20180258087Abstract: The invention provides compounds of formula (I): which contain a 4-membered heterocyclic amide, where the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat respiratory diseases, and processes and intermediates useful for preparing such compounds.Type: ApplicationFiled: March 8, 2018Publication date: September 13, 2018Applicant: THERAVANCE BIOPHARMA R&D IP, LLCInventors: PAUL R. FATHEREE, GARY E.L. BRANDT, CAMERON SMITH, STEVEN D.E. SULLIVAN, LORI JEAN VAN ORDEN, MELANIE A. KLEINSCHEK, GLENN D. CRATER
-
Publication number: 20180258088Abstract: The invention provides compounds of formula (I): where the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat respiratory diseases, and processes and intermediates useful for preparing such compounds.Type: ApplicationFiled: March 8, 2018Publication date: September 13, 2018Applicant: THERAVANCE BIOPHARMA R&D IP, LLCInventors: PAUL R. FATHEREE, GARY E.L. BRANDT, CAMERON SMITH, STEVEN D.E. SULLIVAN, LORI JEAN VAN ORDEN, MELANIE A. KLEINSCHEK, GLENN D. CRATER
-
Publication number: 20170121327Abstract: The invention provides compounds of formula (I): wherein X is and the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat respiratory diseases, and processes and intermediates useful for preparing such compounds.Type: ApplicationFiled: November 2, 2016Publication date: May 4, 2017Applicant: THERAVANCE BIOPHARMA R&D IP, LLCInventors: Paul R. Fatheree, John R. Jacobsen, Anne-Marie Beausoleil, Gary E. Brandt, Melissa Fleury, Lan Jiang, Cameron Smith, Steven D.E. Sullivan, Lori Jean Van Orden, Pierre-Jean Colson, Gene Timothy Fass, Miroslav Rapta, Noah Benjamin, Marta Dabros, Venkat R. Thalladi
